Clinical Trial Update: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tucidinostat in combination with tislelizumab as first-line treatment for advanced Non-Small Cell Lung Cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• Tucidinostat (tucidinostat)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED